EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development and biophysical characterization of a humanized FSH–blocking monoclonal antibody therapeutic formulated at an ultra-high concentration

Satish Rojekar iD, Anusha R Pallapati, Judit Gimenez-Roig, Funda Korkmaz, Farhath Sultana, Damini Sant, Clement M Haeck iD, Anne Macdonald, Se-Min Kim, Clifford J Rosen iD, Orly Barak, Marcia Meseck und 4 weitere

eLife · 2023

DOI: 10.7554/elife.88898 ↗

Kurz gefasst

Fachartikel in der Zeitschrift eLife, 2023. Verfasst von Satish Rojekar und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Medicine and Pharmacology, Icahn School of Medicine at Mount Sinai, New York, United States. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Follicle Stimulating Hormone. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, NIDDK NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Highly concentrated antibody formulations are oftentimes required for subcutaneous, self-administered biologics. Here, we report the development of a unique formulation for our first-in-class FSH-blocking humanized antibody, MS-Hu6, which we propose to move to the clinic for osteoporosis, obesity, and Alzheimer’s disease. The studies were carried out using our Good Laboratory Practice (GLP) platform, compliant with the Code of Federal Regulations (Title 21, Part 58). We first used protein thermal shift, size exclusion chromatography, and dynamic light scattering to examine MS-Hu6 concentrations between 1 and 100 mg/mL. We found that thermal, monomeric, and colloidal stability of formulated MS-Hu6 was maintained at a concentration of 100 mg/mL. The addition of the antioxidant L-methionine and chelating agent disodium EDTA improved the formulation’s long-term colloidal and thermal stability. Thermal stability was further confirmed by Nano differential scanning calorimetry (DSC). Physiochemical properties of formulated MS-Hu6, including viscosity, turbidity, and clarity, confirmed with acceptable industry standards. That the structural integrity of MS-Hu6 in formulation was maintained was proven through Circular Dichroism (CD) and Fourier Transform Infrared (FTIR) Spectroscopy. Three rapid freeze–thaw cycles at –80 °C/25 °C or –80 °C/37 °C further revealed excellent thermal and colloidal stability. Furthermore, formulated MS-Hu6, particularly its Fab domain, displayed thermal and monomeric storage stability for more than 90 days at 4°C and 25°C. Finally, the unfolding temperature (T m ) for formulated MS-Hu6 increased by >4.80 °C upon binding to recombinant FSH, indicating highly specific ligand binding. Overall, we document the feasibility of developing a stable, manufacturable and transportable MS-Hu6 formulation at a ultra-high concentration at industry standards. The study should become a resource for developing biologic formulations in academic medical centers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalFollicle Stimulating HormoneTemperatureCalorimetry, Differential ScanningViscosityProtein Stability

Stichwörter der Autor:innen

accelerated stabilitybiologicsbiotherapeuticsdifferential fluorescence spectroscopydrug developmentexcipient screeningmedicinemonoclonal antibodynone

Substanzen

Antibodies, MonoclonalFollicle Stimulating Hormone

Autor:innen und Institutionen

  • Center for Translational Medicine and Pharmacology, Icahn School of Medicine at Mount Sinai, New York, United States.
  • Center for Biomedical Research, Population Council, New York, United States.
  • Maine Medical Center Research Institute, Scarborough, United States.

ORCID-Profile: Satish Rojekar, Clement M Haeck, Clifford J Rosen, Mone Zaidi

Förderung

  • NIA NIH HHS
  • NIDDK NIH HHS
  • NIGMS NIH HHS
  • National Institute on Aging
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of General Medical Sciences

Zitieren

APA

Rojekar, S., Pallapati, A. R., Gimenez-Roig, J., Korkmaz, F., Sultana, F., Sant, D., Haeck, C. M., Macdonald, A., Kim, S. M., Rosen, C. J., Barak, O., Meseck, M., Caminis, J., Lizneva, D., Yuen, T., & Zaidi, M. (2023). Development and biophysical characterization of a humanized FSH–blocking monoclonal antibody therapeutic formulated at an ultra-high concentration. eLife. https://doi.org/10.7554/elife.88898

Vancouver

Rojekar S, Pallapati AR, Gimenez-Roig J, Korkmaz F, Sultana F, Sant D, et al. Development and biophysical characterization of a humanized FSH–blocking monoclonal antibody therapeutic formulated at an ultra-high concentration. eLife. 2023. doi:10.7554/elife.88898

BibTeX
@article{Rojekar2023,
  author = {Rojekar, Satish and Pallapati, Anusha R and Gimenez-Roig, Judit and Korkmaz, Funda and Sultana, Farhath and Sant, Damini and Haeck, Clement M and Macdonald, Anne and Kim, Se-Min and Rosen, Clifford J and Barak, Orly and Meseck, Marcia and Caminis, John and Lizneva, Daria and Yuen, Tony and Zaidi, Mone},
  title = {Development and biophysical characterization of a humanized FSH–blocking monoclonal antibody therapeutic formulated at an ultra-high concentration},
  journal = {eLife},
  year = {2023},
  doi = {10.7554/elife.88898}
}
Kostenlos starten →